Pharma Aids (DHA:PHARMAID) Interest Expense: BDT-2.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:PHARMAID Pharma Aids Ltd DHA:PHARMAID
73 GF Score
Price BDT615.60
GF Value BDT760.33
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharma Aids Interest Expense?

Pharma Aids DHA:PHARMAID -0.87% 73 Interest Expense is BDT-2.5 Mil as of Mar. 2026. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT760.33 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharma Aids's interest expense for the three months ended in Mar. 2026 was BDT -0.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-2.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharma Aids's Operating Income for the three months ended in Mar. 2026 was BDT 26.2 Mil. Pharma Aids's Interest Expense for the three months ended in Mar. 2026 was BDT -0.6 Mil. Pharma Aids's Interest Coverage for the quarter that ended in Mar. 2026 was 44.93. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Aids  (DHA:PHARMAID) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Aids's Interest Expense for the three months ended in Mar. 2026 was BDT-0.6 Mil. Its Operating Income for the three months ended in Mar. 2026 was BDT26.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was BDT0.0 Mil.

Pharma Aids's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*26.242/-0.584
=44.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Pharma Aids Interest Expense Historical Data

* Premium members only.

The historical data trend for Pharma Aids's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Aids Interest Expense Chart

Pharma Aids Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.90 -0.38 -0.24 -0.26 -1.75

Pharma Aids Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.62 -0.68 -0.64 -0.58
DHA:PHARMAID
73GF Score
Pharma Aids Ltd DHA:PHARMAID
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Aids Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-2.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of BDT-2.5 Mil mean?
Pharma Aids (DHA:PHARMAID) has a Interest Expense of BDT-2.5 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' Interest Expense too high?
Pharma Aids' current Interest Expense is BDT-2.5 Mil. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Interest Expense compare to ISRG and BDX?
Pharma Aids' Interest Expense of BDT-2.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharma Aids and its competitors. Pharma Aids's current Interest Expense is BDT-2.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT760.33, compared to a current price of BDT615.60 — trading 19% below its estimated fair value. The current Interest Expense is BDT-2.5 Mil. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Interest Expense is BDT-2.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued. The current stock price of BDT615.60 is trading 19% below its estimated GF Value™ of BDT760.33. GuruFocus considers Pharma Aids to be Modestly Undervalued.

Key valuation signals for DHA:PHARMAID:

  • Interest Expense: BDT-2.5 Mil
  • GF Value™: BDT760.33 vs. price of BDT615.60 (19% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Aids Business Description

Address 345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score

Get the complete analysis for DHA:PHARMAID

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT615.60
Price
BDT760.33
GF Value